Department of Laboratory Medicine, Liuzhou Maternity and Child Healthcare Hospital, Liu Zhou, Guang Xi, People's Republic of China.
Shaanxi Jiuzhou Biomedical Science and Technology Group, Xi'an, Shaan Xi, People's Republic of China.
Drug Des Devel Ther. 2021 Sep 15;15:3927-3936. doi: 10.2147/DDDT.S323107. eCollection 2021.
Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology with a high rate of disability. Traditional treatments for RA remain a challenging issue. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) have no therapeutic effects on joint destruction, and the prominent side effects include gastrointestinal symptoms. RA is characterized by recurrence and bone attrition. Therefore, regenerative medicine and the use of umbilical cord mesenchymal stem cell (UC-MSC) therapies have recently emerged as potential options. UC-MSCs are multifunctional stem cells that are present in neonatal umbilical cord tissue and can differentiate into many kinds of cells, which have broad clinical application prospects in the tissue engineering of bone, cartilage, muscle, tendon, ligament, nerve, liver, endothelium, and myocardium. Moreover, UC-MSCs have advantages, such as convenient collection of materials and no ethical disputes; thus, these cells have attracted increasing attention from researchers. However, there are few clinical studies regarding UC-MSC therapy for RA. In this paper, we will review traditional drugs for RA treatment and then focus on UC-MSC therapy for RA, including preclinical and clinical UC-MSC applications for RA patients in the context of regenerative medicine. Finally, we will summarize the challenges and perspectives of UC-MSCs as a potential therapeutic strategy for RA. This review will help to design and discover more potent and efficacious treatments for RA patients and aid in advancing this class of cell therapy.
类风湿关节炎（RA）是一种病因不明的自身免疫性疾病，致残率高。RA 的传统治疗仍然是一个具有挑战性的问题。例如，非甾体抗炎药（NSAIDs）对关节破坏没有治疗作用，突出的副作用包括胃肠道症状。RA 的特点是复发和骨质流失。因此，再生医学和脐带间充质干细胞（UC-MSC）治疗最近成为潜在的选择。UC-MSCs 是多能干细胞，存在于新生儿脐带组织中，可以分化为多种细胞，在骨、软骨、肌肉、肌腱、韧带、神经、肝、内皮和心肌等组织工程中有广泛的临床应用前景。此外，UC-MSCs 具有取材方便、无伦理争议等优点，因此引起了研究人员的越来越多的关注。然而，关于 UC-MSC 治疗 RA 的临床研究较少。本文将回顾 RA 治疗的传统药物，然后重点介绍 UC-MSC 治疗 RA，包括再生医学背景下 UC-MSC 治疗 RA 患者的临床前和临床应用。最后，我们将总结 UC-MSCs 作为 RA 潜在治疗策略的挑战和前景。本综述将有助于设计和发现更有效和有效的 RA 患者治疗方法，并有助于推进这一类细胞治疗。
